Announcements Trials
Browse Landscape

Phase

Phase 1 17Phase 3 5Phase 2 5Phase 1/2 3Phase 4 2Phase 2/3 2

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 2UNKNOWN 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 74Other solid neoplasm 18Gastrointestinal 15CNS 7Breast 7Head & Neck 4Genitourinary 4Dermatologic 4Tumor-Agnostic 3Gynecologic 3

Conditions

Neoplasms 2Carcinoma, Squamous Cell 1Adenocarcinoma 1

Interventions

pembrolizumab 18Nivolumab 18Gemcitabine 9Ipilimumab 8Cisplatin 8Carboplatin 8Capecitabine 8Paclitaxel 6Cetuximab 6atezolizumab 5Irinotecan 5Docetaxel 5Cyclophosphamide 5Bevacizumab 5avelumab 4Trastuzumab 4Fluorouracil 4trametinib 3spartalizumab 3Specimen Handling 3Pemetrexed 3Leucovorin 3Everolimus 3Dexamethasone 3Biopsy 3urelumab 2toripalimab 2tislelizumab 2ribociclib 2repotrectinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1/2 × Pemetrexed × Tumor-Agnostic × Clear all
NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Bristol-Myers Squibb

Phase 1/2 Completed
68 enrolled 27 charts
Tumor-Agnostic

Neoplasms

NCT04717375 2025-08-07

Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors

Sanofi

Phase 1/2 Terminated
125 enrolled
Tumor-Agnostic

Neoplasms

NCT03636685 2018-08-17

Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC

ChineseAMS

Phase 1/2 Unknown
60 enrolled
Tumor-Agnostic

Adenocarcinoma, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡